BAY-1217389
BAY-1217389 Basic information
- Product Name:
- BAY-1217389
- Synonyms:
-
- BAY-1217389 BAY 1217389， BAY 1217389）
- CS-2361
- BAY-1217389
- Benzamide, N-cyclopropyl-4-[6-(2,3-difluoro-4-methoxyphenoxy)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-b]pyridazin-3-yl]-2-methyl-
- AY-1217389
- BAY1217389, 10 mM in DMSO
- BAY1217389 (BAY 1217389
- BAY 1217389 ，S8215
- CAS:
- 1554458-53-5
- MF:
- C27H24F5N5O3
- MW:
- 561.5
- Mol File:
- 1554458-53-5.mol
BAY-1217389 Chemical Properties
- Density
- 1.47±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMF: 25 mg/ml; DMF:PBS (pH 7.2)(1:3): 0.25 mg/ml; DMSO: 15 mg/ml
- form
- A crystalline solid
- pka
- 14.58±0.20(Predicted)
- color
- White to off-white
BAY-1217389 Usage And Synthesis
Uses
N-Cyclopropyl-4-[6-(2,3-difluoro-4-methoxyphenoxy)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide inhibits monopolar spindle 1, which is a serine/threonine/tyrosine kinase involved in cell division. It is also a potential antitumor agent.
in vivo
BAY 1217389 achieves moderate efficacy in monotherapy in tumor xenograft studies. However, in line with its unique mode of action, when combines with paclitaxel, low doses of Mps1 inhibitor reduces paclitaxel-induced mitotic arrest in line with weakening of SAC activity. As a result, combination therapy strongly improves efficacy over paclitaxel or Mps1 inhibitor monotreatment at the respective MTDs in a broad range of xenograft models including those showing acquired or intrinsic paclitaxel-resistance. BAY 1217389 shows good tolerability without adding toxicity to paclitaxel monotherapy[1].
IC 50
Mps1: 0.63 nM (IC50)
BAY-1217389Supplier
- Tel
- sales@boylechem.com
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Tel
- 18993966060
- sales@techbiochem.com
- Tel
- 021-52996696，15000506266 15000506266
- Tel
- 028-86040038 13980902949;
- market@dingdangchem.com